I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable outcome rather than bad luck.
The arithmetic in one line: half-life about a week, so steady state at four to five weeks, so a four-week interval is one steady state per step. Two-week intervals mean every step is dosed onto a rising curve.
The bit I cannot resolve on my own is what the trials actually did with participants who could not tolerate a step, because that is the situation I am in and the protocol summaries skip it.
I have searched first, so if this is covered somewhere point me at it and I will read it.
Taking the question as asked, rather than the general version of it. The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks later. The end point of the ladder is set by tolerability, not by a schedule, and there is no evidence that reaching the top faster produces a better outcome.
I would rather be corrected than agreed with, if it comes to it.
PeptideChemSF said:The trials generally allowed a step to be held or reduced and then retried, and people who did that mostly arrived at the same place a few weeks…
That is right for the weekly injectables. For the daily agents the interval logic is different and the four-week convention does not transfer.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsKevinCompounds said:I titrated faster than the label because I felt fine, hit a wall at the third step, and had to come back down — which I now think was the predictable…
Can confirm the pattern KevinCompounds describes. Four weeks is the pharmacokinetics, not caution. With a one-week half-life you need four to five half-lives to reach steady state, so at two weeks you are dosing on top of a concentration that has not finished rising. Escalating then stacks exposure and you get the side-effect burden of the higher dose before you have seen the benefit of the current one.
Clinical perspective, offered as context rather than as advice.
Dose escalation anxiety for titration: I was terrified to move from 0.5mg to 1.0mg based on horror stories in this forum. But my actual experience? Slightly more appetite suppression, zero additional side effects.
Remember that the people posting about terrible side effects are a biased sample. Most people titrate up without drama — they just don't post about it because it's uneventful.